3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Multiple Myeloma
95
Recurrence
11
Neoplasms, Plasma Cell
9
Immunoglobulin Light-chain Amyloidosis
6
Neoplasms
5
Smoldering Multiple Myeloma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Waldenstrom Macroglobulinemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmacytoma
2
Neoplasm, Residual
2
Lymphoma
2
Leukemia, Plasma Cell
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Renal Insufficiency
1
Prostatic Neoplasms
1
Plasmablastic Lymphoma
1
Paraproteinemias
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Myelodysplastic Syndromes
1
Microsatellite Unstable Colorectal Cancer
1
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Hypergammaglobulinemia
1
Disease
1
Chromosome 17 deletion
1
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Microsatellite Unstable Colorectal Cancer
×
daratumumab
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA